Generic drugs in cardiology: Will they reduce health care costs?

Journal of the American College of Cardiology

Volumn 44, Issue 1, 2004, Pages 10-13

  Pitt, Bertram ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b 3214 Taubman Center ^*  (United States)

Author keywords

ACC AHA; ACE; American College of Cardiology American Heart Association; angiotensin converting enzyme; heart failure; HF; left ventricular; LV; RALES; Randomized Aldactone Evaluation Study

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE;

ACADEMIC ACHIEVEMENT; CARDIOLOGY; CLINICAL TRIAL; DOSE RESPONSE; DRUG COST; DRUG USE; GOVERNMENT; HEALTH CARE COST; HEALTH EDUCATION; HUMAN; HYPERKALEMIA; MEDICAL EDUCATION; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

CARDIOLOGY; DRUG UTILIZATION; DRUGS, GENERIC; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HUMANS; PRESCRIPTIONS, DRUG;

EID: 3242805997     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.04.016     Document Type: Review

References (16)

1. Stafford R., Saglam D., Blumenthal D. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med. 157:1997;2460-2462
2. Ayanian J., Hauptman P.J., Guadagnoli E., Antman E.M., Pashos C.L., McNeil B.J. Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med. 331:1994;1136-1142
3. Frye R., Brooks M., Nesto R. Bypass Angioplasty Revascularization Investigation. Gap between clinical trials and clinical practice. Lessons from the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 107:2003;1837-1839
4. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 341:1999;709-717
5. Bozkurt B., Agoston I., Knowlton A.A. Complications of inappropriate use of spironolactone in heart failure When an old medicine spirals out of new guidelines. J Am Coll Cardiol. 41:2003;211-214
6. Berry C., McMurray J.J. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart. 85:2001;E8
7. Georges B., Beguin C., Jadoul M. Spironolactone and congestive heart failure. Lancet. 355:2000;1369-1370
8. McMullan R., Silke B. Spironolactone prescribing in heart failure Comparison between general medical patients and those attending a specialist left ventricular dysfunction clinic. Ulster Med J. 70:2001;111-115
9. Schepkens H., Vanholder R., Billiouw J.M., et al. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone An analysis of 25 cases. Am J Med. 110:2001;438-441
10. Tamirisa K., Aaronson K., Cody R., Koelling T. Spironolactone induced renal impairment and hyperkalemia in patients with heart failure Can we predict these side effects. (abstr)? J Am Coll Cardiol. 41:(Suppl 6):2003;162A
11. Siegel D., Lopez J., Meier J., et al. Academic detailing to improve antihypertensive prescribing patterns. Am J Hypertens. 16:2003;508-511
12. Farquharson C.A., Struthers A.D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 101:2000;594-597
13. MacFaden R.J., Barr C.S., Struthers A.D. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 35:1997;30-34
14. Duprez D.A., De Buyzere M.L., Rietzschel E.R., et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. (comments) Eur Heart J. 19:1998;1371-1376
15. Yee K.M., Pringle S.D., Struthers A.D. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol. 37:2001;1800-1807
16. Modena M.G., Aveta P., Menozzi A., et al. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J. 141:2001;41-46